Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

JUPITER, Fla. – (NewMediaWire) – November 16, 2021 – Marizyme Inc. (“Marizyme”

or the “Company”) (OTCQB:MRZM),
is pleased to announce the hiring of Mr. David Barthel as the Chief

Executive Officer for Marizyme. In his role Mr. Barthel will look to advance

the Company’s technology pipeline and stay committed to

commercialization efforts of DuraGraft in Europe and Asia while focusing on the

FDA submissions for DuraGraft and MATLOC 1 in the US. In addition, Mr. Barthel

will lead the Company through its financing initiatives, strengthening the financial position of the Company in preparation

for an anticipated Nasdaq listing in 2022.


Barthel founded The SmartPill Corp. and led the company as CEO & President

until its acquisition by medical device giant, Medtronic. Mr. Barthel

successfully took The SmartPill company, developing an innovative ingestible sensor-based

capsule for diagnosing GI motility disorders, from its initial patent, through

the entire product development process, raising more than $70 million in

multiple funding rounds. Mr. Barthel led his team through multiple clinical

trials, manufacturing, FDA approval, commercialization and successful insurance

reimbursement.  After the acquisition by

Medtronic, Mr. Barthel joined the company as Area Vice President, GIH Southeast




recently, Mr. Barthel was CEO of Health Logic Interactive Inc. (“Health

Logic”) and its wholly owned Subsidiary, My Health Logic Inc. (“My Health

Logic”), a company focused on developing an innovative point-of-care lab-on-chip

digital diagnostic device technologies for chronic kidney disease.  In less than a year, Mr. Barthel led the Company

from an initial patent pending technology with proof-of-concept data to

building an IP portfolio and further advancing our lab-on-chip technology platform.

The Company also began development on its point-of-care device, MATLOC 1, which

is expected to have a functional prototype ready for its clinical trials to

take place in Q3 2022. Mr. Barthel was responsible for implementing product and

software development partners, the preparation of an FDA pre-submission,

leading discussions with several potential strategic partners, integrating a

strong clinical and business team-based culture, and a diverse Scientific

Advisory Board. He has also developed the business plan around the utilization

of multiple partners for commercialization with the potential for multiple

revenue streams that will ensure eventual success of the device. My Health

Logic Inc., subsidiary of Health Logic which holds the MATLOC device technology

and all accompanying agreements, is currently in the process of being acquired

by Marizyme.



Barthel earned a Bachelor of Arts Degree from St. Norbert College in De Pere,

Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest,



Dr. Vithal Dhaduk, (Chairman) of the Board of Directors, stated the

following: “
We are very

excited about acquiring My Health Logic and David Barthel becoming our CEO. My

Health Logic developed the MATLOC technology, an innovative technology

that has strong potential to improve the lives of millions of patients

with chronic kidney disease.  Bringing on the very dedicated and effective

management group led by David Barthel will add strength to Marizyme’s

current team.

This is a very strategic step for Marizyme to diversify and improve

Marizyme’s current product portfolio by adding more innovative,

platform technologies and a strong management team. We are looking forward

to bringing these new technologies to the market to serve a unique and unmet

need in the chronic kidney and cardiac disease population.”  

About Marizyme, Inc.

Marizyme is an

integrated life sciences company dedicated to the acquisition, development and

commercialization of therapies that minimize mortality and costs in the acute

care space. The Company’s flagship product, DuraGraft®, is an

intra-operative vascular graft storage solution that inhibits endothelial

damage and leads to improved clinical outcomes by reducing the incidence of

complications associated with vein graft failure in bypass surgery. DuraGraft

enhances coronary artery bypass grafting (CABG) surgical outcomes by

significantly reducing major adverse cardiac events such as repeat

revascularization and myocardial infarction. DuraGraft is approved for use in

the EU and several Asian countries but is not yet approved for use in the U.S.

Marizyme is also focused on the development and marketing of products based on

its clinically tested and previously patented protease based therapeutic

Krillase® platform. Krillase is not approved for use in the

U.S. For more information about Marizyme, visit

Forward-Looking Statements

This press release may contain

certain forward-looking statements, including those relating to the Marizyme’s

product development, clinical and regulatory timelines, market opportunity,

competitive position, possible or assumed future results of operations,

business strategies, potential growth 

opportunities and other statements that are predictive in nature. The

Company has made every reasonable effort to ensure the information and

assumptions on which these statements are based are current, reasonable, and

complete. However, a variety of factors, many of which are beyond the  Company’s control, affect the Company’s

operations, performance, business strategy and results and  there can be no assurances that the Company’s

actual results will not differ materially from those indicated herein.

Additional written and oral forward-looking statements may be made by the

Company from time to time. Forward-looking statements may be identified by the

use of forward-looking expressions, including, but not limited to, “expect,”

“anticipate,” “intend,” “plan,” “believe,” “estimate,”  “potential,” “predict,” “project,” “should,”

“would” and similar expressions and the negatives of those terms. These

statements relate to future events or our financial performance and involve

known and  unknown risks, including those

risks set forth in the Company’s risk factor disclosure in the reports that

Marizyme files with the Securities and Exchange Commission (SEC File No.

000-53223), uncertainties, and other factors which may cause actual results,

performance or achievements to be materially different from any future results,

performance or achievements expressed or implied by the forward-looking

statements. Prospective investors are cautioned not to place undue reliance on

such forward-looking statements, which speak only as of the date of this press

release. The Company undertakes no obligation to publicly update any

forward-looking statement, whether as a result of new information, future

events or otherwise.


Bradley Richmond


Source link

The post Marizyme is Pleased to Announce the Appointment of David Barthel as CEO first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button